The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

tranzyme.com

Founded Year

1998

Stage

IPO | IPO

Total Raised

$54.3M

Date of IPO

4/4/2011

Market Cap

0.05B

About Tranzyme Pharma

Tranzyme is a biopharmaceutical company developing small molecule therapeutics for the treatment of gastrointestinal and metabolic disorders.

Tranzyme Pharma Headquarter Location

4819 Emperor Boulevard Suite 400

Durham, North Carolina, 27703,

United States

919-313-4760

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Tranzyme Pharma Patents

Tranzyme Pharma has filed 10 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/26/2009

10/15/2013

Macrocycles, Drug discovery, Hormonal agents, Chelating agents, Peptides

Grant

Application Date

5/26/2009

Grant Date

10/15/2013

Title

Related Topics

Macrocycles, Drug discovery, Hormonal agents, Chelating agents, Peptides

Status

Grant

Latest Tranzyme Pharma News

Tranzyme Pharma Inc. formerly Neokimia Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Nov 27, 2016

Advertisement Topics   Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Tranzyme Pharma, Inc. formerly Neokimia Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 23:18 EST 26 Nov 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Tranzyme Pharma, Inc. formerly Neokimia Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Tranzyme Pharma, Inc. formerly Neokimia Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Tranzyme Pharma, Inc. formerly Neokimia Inc. since January 2007. Key Findings Provides intelligence on Tranzyme Pharma, Inc. formerly Neokimia Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Tranzyme Pharma, Inc. formerly Neokimia Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Tranzyme Pharma, Inc. formerly Neokimia Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Tranzyme Pharma, Inc. formerly Neokimia Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

  • When was Tranzyme Pharma founded?

    Tranzyme Pharma was founded in 1998.

  • Where is Tranzyme Pharma's headquarters?

    Tranzyme Pharma's headquarters is located at 4819 Emperor Boulevard, Durham.

  • What is Tranzyme Pharma's latest funding round?

    Tranzyme Pharma's latest funding round is IPO.

  • How much did Tranzyme Pharma raise?

    Tranzyme Pharma raised a total of $54.3M.

  • Who are the investors of Tranzyme Pharma?

    Investors of Tranzyme Pharma include Biomedical Structures.

  • Who are Tranzyme Pharma's competitors?

    Competitors of Tranzyme Pharma include Acceleron Pharma, Orexigen Therapeutics, Threshold Pharmaceuticals, FORUM Pharmaceuticals, ActoGeniX and 12 more.

You May Also Like

B
Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

B
BrainCells

BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.

A
Affectis Pharmaceuticals

Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.

K
Kemia

Kemia discovers and develops new, oral small molecule medicines for well-validated, clinically significant targets. Kemia applies proprietary chemistries and medicinal chemistry experience to two large and as yet underdeveloped classes of small molecule drug opportunities -- alpha helix interactions and allosteric kinase inhibitors. These target classes include numerous potential drug discovery targets across major disease areas including inflammation, cancer, HIV, diabetes and bone diseases.

B
Bio3 Research

nnBio3 Research s.r.l. is a private biopharmaceutical company based in Milan, Italy, with a USA subsidiary, Bio3 Research Inc., based in Hayward/CA. Bio3 Research develops new compounds up to IND stage with potential in cardiovascular field. The company is focused in the area of cardiovascular disorders related to HMGB1 (High Mobility Group Box 1) over-expression.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.